Program
Ramucirumab
Also written as “IMC-1121B (ramucirumab)”, “Ramucirumab (IMC-1121B)” and “IMC-1121B”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Breast Neoplasms, led by 6 companies.
Drug pageRamucirumab: every studyMany companies study it; this page follows only the 58 they lead. All 109 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 533 open or running | phase 3since Jun 20, 2008 | Aug 13, 2007 | May 2027phase 2 · NCT05999994 |
| Arog Pharmaceuticalsits history only | 10 open or running | phase 1since Jun 14, 2017 | Jun 14, 2017 | none ahead |
| AstraZenecaits history only | 11 open or running | phase 2since May 5, 2025 | May 5, 2025 | Feb 23, 2029phase 2 · NCT06996782 |
| Innovent Biologicsits history only | 10 open or running | phase 3since Dec 3, 2020 | Dec 3, 2020 | none ahead |
| Merckits history only | 11 open or running | phase 2since May 31, 2024 | May 31, 2024 | May 9, 2028phase 2 · NCT06445972 |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 1since Mar 24, 2023 | Mar 24, 2023 | none ahead |
Also a collaborator on its studies: Daiichi Sankyo and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 43 studies since Aug 13, 2007.
- Sep 25, 2015Phase 1 study in NeoplasmsEli Lilly · NCT02564198 · 29 enrolled · United States
- Mar 14, 2016Phase 2 study in Biliary Tract NeoplasmsEli Lilly · NCT02711553 · 309 enrolled · United States, Argentina, Australia and more
- May 31, 2016Phase 1 study in Carcinoma, Non-Small-Cell LungEli Lilly · NCT02789345 · 29 enrolled · United States, France, Korea, Republic of and more
- Jul 11, 2016Phase 2 study in Carcinoma, Non-Small-Cell LungEli Lilly · NCT02831491
- Sep 8, 2016Phase 3 study in Gastroesophageal Junction AdenocarcinomaEli Lilly · NCT02898077 · 440 enrolled · China, Malaysia, Philippines and more
- Jun 14, 2017Arog Pharmaceuticals’ first study: phase 1 study in Esophagogastric AdenocarcinomaNew to Arog PharmaceuticalsArog Pharmaceuticals · NCT03193918 · 30 enrolled · United States
- Oct 29, 20192 phase 2 studiesEli Lilly · NCT04145700, NCT04145349
- Jul 30, 2020Phase 1 study in HealthyEli Lilly · NCT04495478 · 50 enrolled · United States
- Sep 16, 2020Phase 1 study in Advanced Solid TumorEli Lilly · NCT04557384 · 3 enrolled · United States, Japan
- Dec 3, 2020Innovent Biologics’ first study: phase 3 study in Gastric AdenocarcinomaNew to Innovent BiologicsInnovent Biologics · NCT04675983 · 36 enrolled · China
- Mar 24, 2023Sino Biopharmaceutical’s first study: phase 1 study in Stomach NeoplasmsNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT05800418 · 88 enrolled · China
- Aug 14, 2023Phase 2 study in NeoplasmsEli Lilly · NCT05999994 · 105 planned · United States, Australia, Belgium and more
- May 31, 2024Merck’s first study: phase 2 study in Esophageal NeoplasmsNew to MerckMerck · NCT06445972 · 210 planned · United States, Brazil, Chile and more
- May 5, 2025AstraZeneca’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to AstraZenecaAstraZeneca · NCT06996782 · 152 planned · United States, Belgium, Brazil and more
Ahead
- May 2027Primary completion: phase 2 study in NeoplasmsEli Lilly · NCT05999994
- May 9, 2028Primary completion: phase 2 study in Esophageal NeoplasmsMerck · NCT06445972
- Feb 23, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06996782
TargetBeta
“A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity”NCIt, by rule
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule
Other programs on KDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| cabozantinibrule | Exelixis | phase 4 | 36 |
| apatinibrule | Jiangsu HengRui Medicine | phase 3 | 47 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| vorolanibrule | Betta Pharmaceuticals | phase 3 | 24 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
| Aurora B/VEGFR/FGFR Inhibitor AL8326rule | advenchen-laboratories-nanjing-ltd | phase 3 | 8 |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | beijing-konruns-pharmaceutical-co-ltd | phase 3 | 7 |
Studies
All 58 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06996782Carcinoma, Non-Small-Cell Lung · United States, Belgium, Brazil and more | 2 | Recruiting | AstraZeneca | Feb 23, 2029 | 152 |
| NCT06445972Esophageal Neoplasms · United States, Brazil, Chile and more | 2 | Recruiting | Merck | May 9, 2028 | 210 |
| NCT05999994Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Eli Lilly | May 2027 | 105 |
| NCT05800418Stomach Neoplasms · China | 1 | Completed | Sino Biopharmaceutical | Feb 18, 2020 | 88 |
| NCT04675983Gastric Adenocarcinoma · China | 3 | Terminated | Innovent Biologics | Feb 12, 2023 | 36 |
| NCT04557384Advanced Solid Tumor · United States, Japan | 1 | Terminated | Eli Lilly | May 25, 2021 | 3 |
| NCT04495478Healthy · United States | 1 | Completed | Eli Lilly | May 9, 2021 | 50 |
| NCT04145700Sarcoma, Synovial · United States, Australia, Belgium and more | 2 | Terminated | Eli Lilly | Feb 23, 2023 | 23 |
| NCT04145349Desmoplastic Small Round Cell Tumor · United States, Australia, Germany and more | 2 | Completed | Eli Lilly | Jun 14, 2024 | 30 |
| NCT03193918Esophagogastric Adenocarcinoma · United States | 1 | Completed | Arog Pharmaceuticals | Jul 15, 2020 | 30 |
| NCT02898077Gastroesophageal Junction Adenocarcinoma · China, Malaysia, Philippines and more | 3 | Completed | Eli Lilly | Jun 30, 2020 | 440 |
| NCT02831491Carcinoma, Non-Small-Cell Lung | 2 | Withdrawn | Eli Lilly | Jul 2017 | 0 |
| NCT02789345Carcinoma, Non-Small-Cell Lung · United States, France, Korea, Republic of and more | 1 | Completed | Eli Lilly | Oct 19, 2017 | 29 |
| NCT02711553Biliary Tract Neoplasms · United States, Argentina, Australia and more | 2 | Active, not recruiting | Eli Lilly | Feb 16, 2018 | 309 |
| NCT02564198Neoplasms · United States | 1 | Completed | Eli Lilly | Jul 16, 2019 | 29 |
| NCT02539225Metastatic Gastric Adenocarcinoma · Japan, Korea, Republic of, Taiwan | 2 | Completed | Eli Lilly | Oct 25, 2017 | 191 |
| NCT02514551Stomach Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Eli Lilly | Oct 27, 2017 | 245 |
| NCT02443883Stomach Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Eli Lilly | Nov 18, 2016 | 164 |
| NCT02443324Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more | 1 | Completed | Eli Lilly | Aug 31, 2018 | 175 |
| NCT02435433Carcinoma, Hepatocellular · United States, Australia, Austria and more | 3 | Completed | Eli Lilly | Mar 15, 2018 | 399 |
| NCT02426125Carcinoma, Transitional Cell · United States, Australia, Belgium and more | 3 | Completed | Eli Lilly | Apr 21, 2017 | 530 |
| NCT02411448Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more | 3 | Active, not recruiting | Eli Lilly | Jan 23, 2019 | 545 |
| NCT02314117Metastatic Gastric Adenocarcinoma · United States, Argentina, Belgium and more | 3 | Completed | Eli Lilly | Jan 17, 2017 | 645 |
| NCT02082210Liver Neoplasms · United States | 2 | Completed | Eli Lilly | Dec 5, 2017 | 97 |
| NCT02079636Carcinoma, Non-Small-Cell Lung · United States, Spain | 1 | Completed | Eli Lilly | May 2, 2018 | 142 |
| NCT02069041Carcinoma, Hepatocellular · Taiwan | 1 | Completed | Eli Lilly | Sep 2016 | 8 |
| NCT01983878Stomach Neoplasms · Japan | 2 | Completed | Eli Lilly | Jan 2015 | 36 |
| NCT01703091Non-small Cell Lung Cancer Metastatic · Japan | 2 | Completed | Eli Lilly | Dec 2014 | 197 |
| NCT01682135Solid Tumor · China | 1 | Completed | Eli Lilly | Mar 2015 | 28 |
| NCT01634555Solid Tumors · United States | 2 | Completed | Eli Lilly | Aug 2013 | 29 |
| NCT01567163Malignant Solid Tumor · United States | 2 | Completed | Eli Lilly | Dec 2012 | 22 |
| NCT01515306Malignant Solid Tumor · United States | 2 | Completed | Eli Lilly | Mar 20, 2013 | 48 |
| NCT01427933Breast Neoplasms · United States | 2 | Completed | Eli Lilly | Sep 2013 | 141 |
| NCT01286818Colorectal Neoplasms · Japan | 1 | Completed | Eli Lilly | Feb 2012 | 6 |
| NCT01282463Urethral Neoplasms · United States, Canada | 2 | Completed | Eli Lilly | Feb 2015 | 148 |
| NCT01256567Breast Neoplasms · Japan | 1 | Completed | Eli Lilly | Nov 2012 | 7 |
| NCT01253525Adenocarcinoma · Japan | 1 | Completed | Eli Lilly | Oct 2011 | 6 |
| NCT01246960Stomach Neoplasms · United States | 2 | Completed | Eli Lilly | Sep 2013 | 168 |
| NCT01234402Breast Neoplasms · United States, Canada | 2 | Completed | Eli Lilly | Oct 2013 | 153 |
| NCT01183780Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jul 17, 2014 | 1,072 |
| NCT01170663Stomach Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jul 2013 | 665 |
| NCT01168973Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more | 3 | Completed | Eli Lilly | Dec 2013 | 1,253 |
| NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Completed | Eli Lilly | Jan 2014 | 280 |
| NCT01140347Carcinoma, Hepatocellular · United States, Australia, Austria and more | 3 | Completed | Eli Lilly | Mar 2014 | 565 |
| NCT01111604Colonic Neoplasms · United States, Canada | 2 | Completed | Eli Lilly | Dec 2013 | 158 |
| NCT01017731Neoplasms · United States | 2 | Completed | Eli Lilly | Apr 2010 | 68 |
| NCT01005355Advanced Solid Tumors · Japan | 1 | Completed | Eli Lilly | Feb 2011 | 15 |
| NCT00917384Stomach Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jul 2012 | 355 |
| NCT00862784Colorectal Neoplasms · Canada, Spain | 2 | Completed | Eli Lilly | Apr 2011 | 48 |
| NCT00793975Neoplasms · United States | 1 | Completed | Eli Lilly | Jun 2009 | 37 |
| NCT00786383Neoplasms · United States | 1 | Completed | Eli Lilly | Jan 2009 | 25 |
| NCT00735696Carcinoma, Non-Small-Cell Lung · United States, United Kingdom | 2 | Completed | Eli Lilly | Oct 2011 | 41 |
| NCT00721162Ovarian Neoplasms · United States, United Kingdom | 2 | Completed | Eli Lilly | May 2012 | 60 |
| NCT00703326Breast Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Eli Lilly | Mar 31, 2013 | 1,144 |
| NCT00683475Prostatic Neoplasms · United States | 2 | Completed | Eli Lilly | Sep 2011 | 138 |
| NCT00627042Carcinoma, Hepatocellular · United States | 2 | Completed | Eli Lilly | May 2011 | 42 |
| NCT00533702Melanoma · United States | 2 | Completed | Eli Lilly | May 2011 | 106 |
| NCT00515697Carcinoma, Renal Cell · United States | 2 | Completed | Eli Lilly | May 2011 | 39 |
How it is read
Names in the registry
- “Ramucirumab”, 36 entries
- “IMC-1121B (ramucirumab)”, 4 entries
- “Ramucirumab (IMC-1121B)”, 4 entries
- “IMC-1121B”, 4 entries
- “ramucirumab (IMC-1121B)”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 10 studies
- Stomach Neoplasms, 7 studies
- Neoplasms, 5 studies
- Carcinoma, Hepatocellular, 4 studies
- Breast Neoplasms, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.